ATTO Attovia Therapeutics, Inc.
Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments. The company's products include ATTO-1310, a novel ATTOBODY-based Fc-fusion protein therapeutic that inhibits IL-31; developed for the treatment of chronic pruritic diseases such as CPUO, high-itch AD, cholestatic pruritus, and CKD-aP; ATTO-2306, an ATTOBODY-based, half-life-extended immunoglobulin G (IgG)-fusion protein therapeutic that inhibits IL-13 and IL-31; developed for the treatment of AD and other immune-mediated skin diseases, such as CSU and PN; and ATTO-1091, a trispecific ATTOBODY-based Fc-fusion protein therapeutic that inhibits TL1A, IL-23, and integrin a4ß7; developed for IBD a chronic immune-mediated condition characterized by persistent inflammation of the gastrointestinal tract, includes ulcerative colitis (UC) and crohn's disease (CD). The company was incorporated in 2022 and is based in San Carlos, California.…
Industry Peers
BiotechnologyKey Statistics
About Attovia Therapeutics (NASDAQ: ATTO)
›
Attovia Therapeutics (NASDAQ: ATTO) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 44 employees.
The shares were at 15.13 USD on 13 November 2026. Its 52-week range is 12.98 USD to 28.00 USD: the price is 46.0% below the high and 16.6% above the low.
Its market capitalisation is 691.63M USD.
Attovia Therapeutics reports return on equity of 56.4%.
It holds more cash than debt, a net cash position of 110.81M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 5 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 43.20 USD is 185.5% above the current price. The next earnings report is expected on 3 March 2027.